PMC4720062_01
Histological findings of the non-small cell lung cancer and renal cell carcinoma. (A) Lung: sheets or islands of large polygonal malignant cells with pink cytoplasm and distinct cell borders consistent with squamous cell carcinoma are observed (H&E staining, x200). (B) Kidney: biopsy specimen of the renal mass showed alveolar growth of large polygonal cells with clear cytoplasm, uniform round nuclei, and inconspicuous nucleoli (H&E staining, x200). Neoplastic cells have clear cytoplasm and are arranged in nests with intervening blood vessels, consistent with clear cell carcinoma.
crt-2014-209f1.jpg
PMC4720062_01_crt-2014-209f1.jpg
f1-crt-2014-209
Histological examination of a left bronchial biopsy specimen obtained by bronchoscopy resulted in a diagnosis of squamous cell carcinoma (Fig. 1). A needle biopsy was obtained from the mass in the left kidney, which enabled diagnosis of clear cell RCC (T1bN0M0) (Fig. 1).
Computed tomography findings of the renal cell carcinoma (RCC). (A) A lobulating contoured RCC mass measuring 5x4 cm located in the left kidney is observed at the time of pazopanib initiation. (B) After 8 months of pazopanib treatment, the response of the RCC is considered to be stable disease (5.5x4.8 cm).
crt-2014-209f2.jpg
PMC4720062_01_crt-2014-209f2.jpg
f2-crt-2014-209
At 8 months after initiation of pazopanib, the RCC had progressed slightly but was within the range of stable disease according to Response Evaluation Criteria in Solid Tumor ver. 1.1 (Fig. 2).
Computed tomography findings of the squamous cell lung cancer. (A) A mass measuring 7x3 cm is observed in the left lower lobe of the lung at the time of pazopanib initiation. (B) The mass decreases in size to approximately 3.5x1.5 cm after 8 months of pazopanib treatment. The squamous cell cancer shows an unexpected partial response to pazopanib.
crt-2014-209f3.jpg
PMC4720062_01_crt-2014-209f3.jpg
f3-crt-2014-209
However, the NSCLC showed an unexpected partial response (Fig. 3).